The study focused on patients without actionable genomic alterations whose disease had progressed after prior immunotherapy and platinum-based chemotherapy
Hansoh Pharma will receive an upfront payment in the low double-digit millions
Selected proposals in the innovation challenge will receive funding to develop transformative ideas, tools, and approaches to strengthen early diagnosis and improve patient outcomes
Sac-TMT is a novel human TROP2 ADC with proprietary intellectual property, targeting advanced solid tumors
HER2-mutant NSCLC typically has a poor prognosis and limited treatment options
This is the first and only subcutaneous immune checkpoint inhibitor available in Europe
Takeda will make an upfront payment of $1.2 billion, which includes a $100 million equity investment in Innovent
Results from the Phase 2 PHAROS trial potentially establish new benchmark with targeted combination therapies for this patient population
Roche will unveil the primary results from the phase III evERA Breast Cancer study evaluating giredestrant
Subscribe To Our Newsletter & Stay Updated
